anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
With our USDA partners, we have developed a whole-food, multi-component nutrient bars. Previous pilot studies demonstrated that short-term bar consumption results in favorable increases in HDL-cholesterol (HDL-c), particularly large-HDL (HDL-L) in most lean but only in some overweight/obese individuals. Obesity is associated with poor gastrointestinal health and systemic inflammation, which are also associated with low HDL. Our hypothesis is that a carefully formulated nutritional supplement bar delivered in a whole food matrix can correct micronutrient deficiencies in obese adults and have a beneficial impact on indices of insulin dysregulation and the metabolic syndrome. The aims of this project are 1) to characterize the effect size on indices of lipid profile, homocysteine, inflammation, insulin resistance, micronutrient levels, DNA integrity, hunger and satiety, BMI, waist circumference, and blood pressure with different formulations of CHORI bar taken twice daily for periods ranging from 2-8 weeks. We will also evaluate gut inflammation, redox status, tissue metals, and DNA integrity with novel exploratory assays that may serve as markers for micronutrient malnutrition and chronic disease risk. 2) Where significant improvement in the outcome variables is observed, we will attempt to "deconstruct" the bars and attempt to determine the active ingredients responsible for these changes.
Individuals will be recruited who are currently users of cannabis and alcohol to participate in this study. They will undergo a physical exam at screening. There will be six study visits where the subject will arrive at the Clinical Research Unit(University of Iowa Hospitals \& Clinics) the night before dosing. At each visit subjects will be receive one of the following six dosing regimens: placebo alcohol with placebo cannabis; placebo alcohol with low-dose cannabis, placebo alcohol with higher-dose of cannabis, low dose alcohol with placebo cannabis; low dose alcohol with low dose cannabis, low dose alcohol with higher-dose of cannabis. After dosing, participants will have provide saliva samples and blood drawn periodically to check cannabis levels and will complete a driving simulation. After completing the drive, additional saliva samples and blood draws will occur and participants will be monitored until it is safe to transport home.
The invention discloses an application of a reagent for improving DJ-1 gene expression level in preparation of anti-vascular calcification medicines, and relates to the technical field of biological medicines. The nucleotide sequence of the DJ-1 gene is shown as SEQ ID NO. 1. The research of the invention discovers that the expression quantity of the DJ-1 gene can be improved to inhibit the expression quantity of ALPL, runx2 and BMP2 genes, and further can effectively relieve vascular calcification, thereby effectively reducing the incidence of vascular calcification. The invention provides a new technical means for preventing and treating vascular calcification and has important clinical application value. The invention also clarifies the action mechanism of preventing and treating vascular calcification by taking DJ-1 gene as an action target, and provides powerful technical support for screening medicaments for resisting vascular calcification.
Reperfusion after myocardial ischemia would aggravate myocardial structural and functional damage, known as myocardial ischemia-reperfusion (MI/R) injury. Cinnamamide derivatives have been reported to exert cardioprotective effects, and we have previously reported that compound 7 played a role in cardioprotection against MI/R via anti-inflammatory effect. However, exact mechanism underlying such beneficial action of compound 7 is still unclear. The protective effect of compound 7 was determined in H9c2 cells under H2O2 stimulation with or without nigerin (NLRP3 activator). Electrocardiogram, echocardiography, myocardial infarction size, histopathology and serum biochemical assay were performed in MI/R rats. Metabolomics in vivo and mRNA or protein levels of NLRP3, ASC, cleaved caspase-1 and its downstream IL-18 and IL-1β were detected both in vitro and in vivo. Compound 7 significantly ameliorate H2O2-induced cardiomyocyte damage, which was supported by in vivo data determined by improved left ventricular systolic function and histopathological changes, reduced myocardial infarction area and cellular apoptosis in heart tissue. Cardiac differential metabolites demonstrated that compound 7 indeed altered the cardiac reprogramming of inflammation-related metabolites, which was evidenced by down-regulated cardiac inflammation by compound 7. Additionally, compound 7 alleviated myocardial injury by inhibiting the NLRP3 pathway rather than other members of the inflammasome both in vitro and in vivo, which was further evidenced by CETSA assay. Whereas, nigerin blocked the inhibitory activity of compound 7 against NLRP3. Cinnamamide derivative compound 7 ameliorated MI/R injury by inhibiting inflammation via NLRP3.
KGF is an endogenous protein in the fibroblast growth factor (FGF) family that binds to the KGF receptor. Binding of KGF to its receptor has been reported to result in proliferation, differentiation, and migration of epithelial cells. The KGF receptor, one of four receptors in the FGF family, has been reported to be present on epithelial cells in many tissues examined including the tongue, buccal mucosa, esophagus, stomach, intestine, salivary gland, lung, liver, pancreas, kidney, bladder, mammary gland, skin (hair follicles and sebaceous gland), and the lens of the eye. The KGF receptor has been reported to not be present on cells of the hematopoietic lineage. Endogenous KGF is produced by mesenchymal cells and is upregulated in response to epithelial tissue injury. 

In mice and rats, Kepivance enhanced proliferation of epithelial cells (as measured by Ki67 immunohistochemical staining and BrDU uptake) and demonstrated an increase in tissue thickness of the tongue, buccal mucosa, and gastrointestinal tract. Kepivance has been studied in murine models of chemotherapy and radiation-induced gastrointestinal injury. In such models, administration of Kepivance prior to and/or after the cytotoxic insult improved survival and reduced weight loss compared to control animals. 

Kepivance has been shown to enhance the growth of human epithelial tumor cell lines in vitro at concentrations ≥ 10 mcg/mL (> 15-fold higher than average therapeutic concentrations in humans). In nude mouse xenograft models, three consecutive daily treatments of Kepivance at doses of 1,500 and 4,000 mcg/kg (25- and 67-fold higher than the recommended human dose, respectively) repeated weekly for 4 to 6 weeks were associated with a dose-dependent increase in the growth rate of 1 of 7 KGF receptor-expressing human tumor cell lines.
A bone marrow fluid of a patient is sampled, housed in a collection tube  11  and conveyed into an isolator in a sterile state. In the isolator, the bone marrow fluid in the collection tube is pipetted into test tubes and culture tube, etc. To the bone marrow fluid in the tubes, an erythrocyte sedimentation agent is added. After precipitating erythrocytes, the supernatant is collected. From the collected supernatant, a bone marrow cell-containing fraction for liver regeneration is concentrated and pipetted into flasks which are conveyed into an incubator to start the cell-culture. From the isolator system, test tubes are taken out. The bone marrow fluid in the test tubes and the concentrate are subjected to a safety test, etc.
A system for efficiently providing professional services (an “EBE system”), which is based the concepts of evidence-based medicine and the physician extender model. The EBE system combines and expands these concepts to enable services, which traditionally could only be provided by costly professionals, to be provided by lower cost “extenders.” Under the EBE system, extenders work remotely from and under the supervision of one or more professionals according to protocols developed by the professionals. In addition, the extenders collect data on the effectiveness of the protocols. The feedback of this information to the professional allows the protocols to be monitored and updated and new protocols to be developed. The EBE system may include one or more professional modules, one or more extender modules, and an extender-based system. Further, the EBE system may include a method for providing professional services (an “EBE method”).
PROBLEM TO BE SOLVED: To obtain a serum having a metastasis-controlling action and useful as a metastasis-controlling agent by administering a specific compound to an animal and subsequently collecting blood from the animal. SOLUTION: This serum is obtained by forcibly orally administering a compound of the formula (R<1> is a 1-6C alkyl; R<2> is a 1-10C alkyl, a 3-7C cycloalkyl, etc.; A is CH2 CH2 , CH=CH, etc.; X is O, NH) to a mammalian at a daily dose of 0.0001-80mg/kg everyday for 6-60 days, collecting blood from the mammalian 24hr later after the final administration, subjecting the blood to a centrifugal treatment, and subsequently collecting the serum from the supernatant. A fraction having a mol.wt. of 10000-50000 in the serum has the metastasis- controlling action and is useful, but the active ingredient is unstable to heat and is inactivated, when heated at a temperature of >=60 deg.C for 30min. A metastasis-controlling agent containing the serum as an active ingredient is used by an oral administration method, etc.
PURPOSE:To obtain a beautiful skin hair tonic, containing components of a root sea tangle, Angelica keiskei Koidz. and an aloe, having skin beautifying effects on the skin, usable as a pack and further having hair tonic effects on the hair and usable as a hair treatment. CONSTITUTION:This hair tonic contains, e.g. 500g powder of a root sea tangle which is a sea tangle of brown algae and collected after the passage of several years from the growth, e.g. 800g powder of a leaf of Angelica keiskei Koidz. which is a large-sized perennial herb of the family Umbelliferae, e.g. 200g powder of a root of the Angelica keiskei Koidz., preferably 500cc Camellia oil and, e.g. 3000cc extract from an aloe of the family Liliacea.
The invention "use of biomarker or biomarkers combination in preparing a diagnostic reagent for fulminant myocarditis and a drug for fulminant myocarditis" belongs to the field of disease diagnostic reagents and drugs. The use is characterized in that the biomarker comprises Siglec-5. The biomarkers combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The invention finds that the levels of the biomarker in plasma of patients with fulminant myocarditis is increased, and proves that the biomarker plays a role in diagnosing fulminant myocarditis and a role as a drug target in relieving and/or improving fulminant myocarditis. The level of the biomarker can be detected to forecast or auxiliary diagnose fulminant myocarditis or estimate prognosis of fulminant myocarditis. Meanwhile, level of the biomarkers is controlled through drugs, more intensified diagnosis and follow-up treatment can be carried out on diseases, and the biomarkers have huge clinical application value.
A system for advising an exerciser about his physical activities, associated either with displacement of the exerciser itself or of an object displaced by the exerciser, or an object displaced simultaneously with the exerciser. The system comprises a first unit for monitoring the activities. This unit is not in physical contact with the exerciser or the object, displaced by the exerciser. The first unit is capable to collect raw data defining the activities either in terms of distance or acceleration. The first unit transmits the collected raw data in a wireless fashion to a second unit, which receives the transmitted raw data, processes it and calculates various parameters, defining the said physical activities, and represents the calculated parameters in a form recognizable by the exerciser. The system enables tracking, recording and updating the relevant information, provides improved feedback and thus helps to the exercising individual to improve his performances.
Systems and methods are disclosed herein for computer-aided method of hospitality industry recruitment system. The method allows applicants to upload their profile and availability status and employers can select the employee based in their requirements. The recruiter can select the applicant, designate the job, get the job completed and provide the required dues using the platform. The system provides online tool to display the available resources to recruiters, their details, billing platform and connection with banks for secured transactions. Furthermore, the clients are rated based on aspects of their performance such as hard work, reliability and overall quality of the job. This information is then permanently saved within the interface for creation of realistic ratings.
Peptides of the calcitonin type when obtained by synthesis can be purified in a simple manner by forming inner salts, which precipitate from aqueous solutions of salts of the peptides with acids or bases when these solutions are adjusted to the isoelectric range. Impurities remain in solution, while the inner salts separate practically quantitatively. The precipitation is completed after several hours. The peptides can then be recuperated by treatment with an acid, especially a therapeutically suitable acid. The process affords products which are superior to those obtained by purification methods hitherto known and gives higher yields. Other long-chain peptides such as ACTH, insulin or glucagon cannot be purified in this manner.
Tobramycin inhalation solution, USP should be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Upon removal from the refrigerator, or if refrigeration is unavailable, tobramycin inhalation solution pouches (opened or unopened) may be stored at room temperature [up to 25°C (77°F)] for up to 28 days. Tobramycin inhalation solution, USP should not be used beyond the expiration date stamped on the ampule when stored under refrigeration 2°C to 8°C (36°F to 46°F) or beyond 28 days when stored at room temperature [up to 25°C (77°F)].

Tobramycin inhalation solution, USP ampules should not be exposed to intense light. Tobramycin inhalation solution, USP is light sensitive; unopened ampules should be returned to the foil pouch. The solution in the ampule is colorless to yellow, but may darken with age if not stored in the refrigerator; however, the color change does not indicate any change in the quality of the product as long as it is stored within the recommended storage conditions.
An anticipated twelve subjects will be prescribed a standard clinical dose of spironolactone of 1 mg/kg/day. The spironolactone will be provided as suspension.
A subcutaneous cavity marking device has detectable marker(s) attached to filler(s). Independent claims are included for the following: (a) the above device where the body includes resilient biocompatible material; (b) the above device where the body includes non bioabsorbable suture material and the marker is radiopaque; (c) the above device where the marker is not bioabsorbable and the body is bioabsorbable; (d) a composition having non-toxic non-radioactive microparticles for migrating from an insertion site to a lymph node in under 3 hours. The particles are detectable non-invasively; (e) a cavity marking delivery device having a delivery device in a lumen of a cartridge. The cartridge slides on a disengaging arm; (f) a delivery device having an ejector coupled to an elongate member. The ejector disengages a marking device seated on the member; (g) delivery systems including (f); (h) kits including (a), (b), (c), (d) or (f); (i) marking a tissue cavity using devices as in (a) and (f); (j) marking a tissue cavity using a delivery device to access the cavity and then deploy a remotely detectable device; (k) delivering a marking device into a cavity using a medical instrument probe to install an outer sheath, delivering the device through the sheath and then withdrawing the sheath; (l) delivering a marking device into a cavity using a medical instrument cannula having a side window. The device is ejected through the window by advancing a shaft that remains within the cannula; (m) marking a cavity by inserting a marking device through a small opening; the device expands to mark the borders of the larger cavity; (n) locating a sentinel lymph node by injecting a composition similar to (d); (o) making a cavity marking device by rolling or folding a sheet of bioabsorbable material around a marker; (p) making a cavity marking device by cutting a filler body material to shape, making a hole partway through the material and inserting marker(s) into the hole; (q) locating a sentinel lymph node comprising: (1) injecting a non-invasively detectable, non-radioactive, migratory contrast agent into the region of a cavity or lesion; (2) allowing the contrast agent to migrate to a sentinel lymph node; and (3) identifying the sentinel lymph node by non-invasively detecting the contrast agent in the sentinel lymph node. Preferred Features: The microparticles may be carbon or silicon dioxide.
Cytokines and chemokines are secreted proteins that regulate various biological processes, such as inflammation, immune response, and cell differentiation. Therefore, disruption of signaling pathways involving these proteins has been linked to a range of diseases, including cancer. However, targeting individual cytokines, chemokines, or their receptors is challenging due to their regulatory redundancy and incomplete understanding of their signaling networks. To transform these difficult-to-drug targets into a pharmacologically manageable class, we developed a web-based platform called KinCytE. This platform was designed to link the effects of kinase inhibitors, a well-established class of drugs, with cytokine and chemokine release and signaling networks. The resulting KinCytE platform enables users to investigate protein kinases that regulate specific cytokines or chemokines, generate a ranked list of FDA-approved kinase inhibitors that affect cytokine/chemokine activity, and explore and visualize cytokine signaling network thus facilitating drugging this challenging target class. KinCytE is freely accessible via https://atlas.fredhutch.org/kincyte.
Phase IIa - Dose escalation. 3g cohort and 4.8g cohort run simultaneously, followed by a 6 g cohort. Administered in 600 g capsules of NP-101 for a total daily dose of 3g, 4.8g and 6g adminstered BID. Administered for 14 days.Establish MTDD Phase IIB - Continue study with MTDD as established above.
The present arm received tooth extraction and guided bone regeneration (performed with xenograft porcine material and collagen barrier membrane). After 4 months, a dental implant was inserted.
MPS II (Hunter Syndrome) is a rare X-linked recessive genetic disease caused by mutations in the iduronate-2-sulfatase gene (IDS). Enzyme replacement therapy (ERT) with recombinant idursulfase (ELAPRASE®) is the only approved product for the treatment of Hunter syndrome, however, ERT as currently administered does not cross the blood brain barrier and is therefore unable to address the unmet need in MPS II patients with central nervous system (CNS) (neurocognition and behavior) involvement. RGX-121 is designed to deliver a functional gene to cells in the CNS. Iduronate-2-sulfatase (I2S) may then be secreted by transduced cells, which may then cross-correct non-transduced cells by taking up the functional enzyme.

This is a Phase I/II/III study enrolling in two sequential parts. Part 1 is a Phase I/II, first-in-human, multicenter, open-label, single arm dose escalation study of RGX-121. Three one-time doses of RGX-121 will be studied in up to 16 pediatric subjects who have neuronopathic MPS II. Safety will be the primary focus for the initial 24 weeks after treatment (primary study period) whereupon, subjects will continue to be assessed (safety and efficacy) for up to a total of 104 weeks following treatment with RGX-121. Part 2 is a pivotal expansion, multicenter, open-label, single arm study of RGX-121. A single dose of RGX-121 will be studied in up to 30 pediatric patients who have been diagnosed with neuronopathic MPS II. Subjects will be assessed at various timepoints for 24 months after receiving RGX-121. Subjects will be given the opportunity to enroll in a separate 3-year long-term follow-up study in accordance with the US federal government guidelines for the safety follow-up of patients receiving gene therapy.
Patients will be recruited from those referred to the local site's Diagnostic Imaging Department for SPECT myocardial perfusion imaging (MPI), who have an intermediate to high pre-test likelihood of disease (Diamond-Forrester criteria ≥ 30%) and are clinically indicated to have an MBF study. Research imaging will consist of a SPECT acquisition at the time of rest and stress radiotracer injection in addition to the standard (delayed) clinical stress/rest SPECT scan with 99mTc-tetrofosmin. This is an observational study; patients will be managed according to the standard clinical care of the local site. Where available, a CT scan will also be acquired for attenuation and/or scatter correction. Studies may be one day (rest/stress or stress/rest) or two day (rest and stress on separate days) All studies will be analyzed locally but the raw data will also be anonymized and forwarded to the core facility for reprocessing. Central processing will allow comparison between sites and the repeat processing will provide an estimate of inter-operator variability in the measurements. The core lab will also compare the relative perfusion from immediate and delayed imaging for image quality and diagnostic accuracy (visual and quantitative).
The present invention discloses a pilose deer horn spirit and a processing method thereof, which relates to a spirit and a processing method thereof. Medicinal materials and auxiliary elements in the existing pilose deer horn spirit can influence and destroy components of fresh pilose deer horns and fresh deer placentae. The product of the present invention comprises 96.4 to 97.9 shares of spirit, 1.5 to 2.6 shares of spirit extract of fresh pilose deer horns, and can also contains 0.6 to 1 share of spirit extract of fresh deer placentae. The processing method comprises: fresh pilose deer horns are dried in the air, are sterilized, are soaked in a big spirit pot and are sealed; fresh deer placentae are cleanly washed and are sealed in a big spirit pot; the extract of the fresh pilose deer horns, the extract of the fresh deer placentae and the spirits are mixed. The present invention overcomes the bias against pilose deer horn spirits, and various auxiliary substances in the pilose deer horn spirits are removed. The product has the advantages of pure mouth feeling and no foreign taste, and nutritional ingredients are not influenced or destroyed. The processing method of the present invention is simple and feasible, and can be generalized and utilized.
Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.